M. Casagrande et al. / Bioorg. Med. Chem. 20 (2012) 5965–5979
5979
MTT assay already described.27 The results are expressed as IC50
which is the dose of compound necessary to inhibit cell growth
by 50%. All the tests were performed in duplicate at least three
times.
,
2. Dondorp, A. M.; Yeung, S.; White, L.; Nguon, C.; Day, N. P. J.; Socheat, D.; Von
Seidlein, L. Nat. Rev. Microbiol. 2010, 8, 272.
3. Casagrande, M.; Basilico, N.; Parapini, S.; Romeo, S.; Taramelli, D.; Sparatore, A.
Bioorg. Med. Chem. 2008, 16, 6813.
4. Casagrande, M.; Basilico, N.; Rusconi, C.; Taramelli, D.; Sparatore, A. Bioorg.
Med. Chem. 2010, 18, 6625.
5. Roux, C.; Biot, C. Future Med. Chem. 2012, 4, 783.
6. Biot, C.; Nosten, F.; Fraisse, L.; Ter-Minassian, D.; Khalife, J.; Dive, D. Parasite
2011, 18, 207.
5.33. BHIA Assay
7. Blackie, M. A.; Yardley, V.; Chibale, K. Bioorg. Med. Chem. Lett. 2010, 1078, 20.
8. Forsch, R. A.; Wright, J. E.; Rosowsky, A. Bioorg. Med. Chem. 2002, 10, 2067.
9. Foye, W. O.; Hefferren, J. J. J. Am. Pharm. Assoc. 1954, 43, 602.
10. Park, S.; Kang, Y. Heterocycles 2002, 57, 2393.
11. Salvadori, S.; Fiorini, S.; Trapella, C.; Porreca, F., et al Bioorg. Med. Chem. 2008,
16, 3032.
The inhibition of b-hematin formation by compounds 4a and 10
was carried out using a b-hematin inhibitory activity (BHIA) assay.
The full details of the assay have been published30 and the assay
was performed exactly as described in the indicated reference.
12. Herbivo, C.; Comel, A.; Kirsch, G.; Raposo, M. M. M. Tetrahedron 2009, 65,
2079.
5.34. Determination of physicochemical properties
13. Kauffman, J. M.; Moyna, G. J. Org. Chem. 2003, 68, 839.
14. Shie, T.; Lin, C.; Lin, S.; Yang, D. Eur. J. Org. Chem. 2007, 4831.
15. Young, R.; Mitchell, R.; Brown, T., et al J. Med. Chem. 1988, 31, 656.
16. Awasthi, S.; Mishra, N.; Kumar, B.; Sharma, M.; Bhattacharya, A.; Mishra, L. C.;
Bhasin, V. K. Med. Chem. Res. 2009, 18, 407.
17. Ridge, D. N.; Hanifin, J. W.; Harten, L. A.; Johnson, B. D.; Menschik, J.; Nicolau,
G.; Sloboda, A. E.; Watts, D. E. J. Med. Chem. 1979, 22, 1385.
18. Kauffmann Hefner, I. WO/2008/022945, 2008.
The pKa values of the studied compounds were determined
potentiometrically at 25 °C using a PCA 101 instrument from Sirius
Analytical Instruments (East Sussex, United Kingdom). Compounds
were dissolved in 0.15 M KCl and the resulting solutions acidified
to pH 1.8 with 0.5 M HCl. Titrations were done in triplicate with
0.5 M KOH. Partition coefficients of the compounds in n-octanol–
0.15 M KCl were determined potentiometrically using the same
instrument with three different volume ratios of organic and aque-
ous phases (0.2, 0.4 and 0.6). The pKa, logPOctanol, and logD (distri-
bution coefficient, defined as the ratio of the sum of concentrations
for all solute species in the n-octanol phase to the same of the
aqueous phase at selected pH) values were calculated from the
titration curves using the Refinement Pro software program, v.
1.0 (Sirius Analytical Instruments). Alternatively, logD values
were calculated using the following equation: logD = logPÀ
log[1 + 10(pKa1ÀpH) + 10(pKa1 + pKa2 À 2pH) + 10(pKa1 + pKa2 + pKa3 À 3pH)].36
19. Galal, S. A.; Abd El-All, A. S.; Hegab, K. H.; Magd-El-Din, A. A.; Youssef, N. S.; El-
Diwani, H. I. Eur. J. Med. Chem. 2010, 45, 3035.
20. Xu, Z.; DiCesare, J. C.; Baures, P. W. J. Comb. Chem. 2010, 12, 248.
21. Ragan, J. A.; Burmaster, M.; Hill, P. D. Synlett 2004, 1334.
22. Koerber-Ple, K.; Massiot, G. J. Heteroc. Chem. 1995, 32, 1309.
´
23. Gerona-Navarro, G.; Bonacke, M. A.; Alias, M.; Perez De Vega, M. J.; Garcıa-
López, M. T.; López, P.; Cativiela, C.; González-Muñiz, R. Tetrahedron Lett. 2004,
45, 2193.
24. Kuwano, R.; Takahoshi, M.; Jto, Y. Tetrahedron Lett. 1998, 1017, 39.
25. Rueckle, T.; Biamonte, M.; Grippi-Vallotton, T.; Arkinstall, S.; Cambet, Y.;
Camps, M.; Chabert, C.; Church, D. J.; Halazy, S.; Jiang, X.; Martinou, I.; Nichols,
A.; Sauer, W.; Gotteland, J. P. J.Med. Chem. 2004, 47, 6921.
26. Makler, M. T.; Ries, J. M.; Williams, J. A.; Bancroft, J. E.; Piper, R. C.; Gibbins, B.
L.; Hinrichs, D. J. J. Am. J. Trop. Med. Hyg. 1993, 48, 739.
27. D’Alessandro, S.; Gelati, M.; Basilico, N.; Parati, E. A.; Haynes, R. K.; Taramelli, D.
Toxicology 2007, 241, 66.
Acknowledgments
28. O’Neill, P. M.; Bray, P. G.; Hawley, S. R.; Ward, S. A.; Park, B. K. Pharmacol. Ther.
1998, 77, 29.
29. Warhurst, D. C.; Craig, J. C.; Adagu, I. S.; Meyer, D. J.; Lee, S. Y. Malar. J. 2003, 2,
26.
30. Parapini, S.; Basilico, N.; Pasini, E.; Egan, T. J.; Olliaro, P.; Taramelli, D. Exp.
Parasitol. 2000, 96, 249.
31. Egan, T. J.; Chen, J. Y.; de Villiers, K. A.; Mabotha, T. E.; Naidoo, K. J.; Ncokazi, K.
K.; Langford, S. J.; McNaughton, D.; Pandiancherri, S.; Wood, B. R. FEBS Lett.
2006, 580, 5105.
32. Pisciotta, J. M.; Coppens, I.; Tripathi, A. K.; Scholl, P. F.; Shuman, J.; Bajad, S.;
Shulaev, V.; Sullivan, D. J., Jr. Biochem. J. 2007, 402, 197.
33. Trager, W.; Jensen, J. B. Science 1976, 193, 673.
Part of this manuscript was generated in the context of the
AntiMal project, funded under the 6th Framework Programme of
the European Community (Contract No. IP-018834). The authors
are solely responsible for its content, it does not represent the
opinion of the European Community, and the Community is not
responsible for any use that might be made of the information con-
tained therein. The financial support from the University of Milan
(PUR 2008) is also acknowledged.
34. Sparatore, A.; Basilico, N.; Parapini, S.; Romeo, S.; Novelli, F.; Sparatore, F.;
Taramelli, D. Bioorg. Med. Chem. 2005, 13, 5338.
35. Ades, E. W.; Candal, F. J.; Swerlick, R. A.; George, V. G.; Summers, S.; Bosse, D. C.;
Lawley, T. J. J. Invest. Dermatol. 1992, 99, 683.
We thank the Associazione Volontari Italiani Sangue (AVIS
Comunale Milano) for providing fresh red blood cells for P. falcipa-
rum growth.
36. Van de Waterbeemd, H.; Testa, B. Adv. Drug Design 1987, 16, 85.
References and notes
1. Wongsrichanalai, C.; Meshnick, S. R. Emerg. Infect. Dis. 2008, 14, 716.